Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

8 terminated/withdrawn out of 20 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

20%

4 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

7 terminated

Enrollment Performance

Analytics

Phase 1
10(50.0%)
Phase 2
6(30.0%)
Phase 3
4(20.0%)
20Total
Phase 1(10)
Phase 2(6)
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials
NCT01528137Phase 1Terminated

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Role: collaborator

NCT00473720Phase 1Completed

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

Role: collaborator

NCT00707304Phase 3Completed

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

Role: lead

NCT00093132Phase 1Terminated

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

Role: lead

NCT00450970Phase 3Terminated

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Role: lead

NCT00370383Phase 2Completed

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

Role: lead

NCT00069745Phase 3Completed

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Role: lead

NCT01168882Phase 1Withdrawn

Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies

Role: lead

NCT00313456Phase 1Terminated

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Role: lead

NCT00268970Phase 2Completed

Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Role: lead

NCT00265655Phase 2Completed

Satraplatin for Patients With Metastatic Breast Cancer (MBC)

Role: lead

NCT00125411Phase 1Terminated

Study of Satraplatin (JM-216) in Combination With Docetaxel

Role: lead

NCT00329329Phase 1Terminated

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

Role: lead

NCT00480623Phase 1Terminated

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Role: lead

NCT00706862Phase 3Unknown

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

Role: lead

NCT00854633Phase 1Unknown

Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

Role: lead

NCT01273779Phase 2Suspended

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

Role: lead

NCT00630656Phase 2Completed

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

Role: lead

NCT01220284Phase 1Unknown

Satraplatin and Vinorelbine in Advanced Solid Tumors

Role: collaborator

NCT00095186Phase 2Completed

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

Role: lead

All 20 trials loaded